Iladac DSR Capsule PR is a combination pharmaceutical formulation containing Domperidone 30 mg and Ilaprazole 10 mg, designed for the management of gastroesophageal reflux disease (GERD), peptic ulcers, and related acid peptic disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Ilaprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting ulcer healing and symptom relief. The combination provides synergistic effects by addressing both acid suppression and motility enhancement, improving therapeutic outcomes in patients with acid-related dyspepsia and delayed gastric emptying. Iladac DSR Capsule PR is indicated for adults requiring effective control of acid secretion alongside prokinetic support. It should be administered as prescribed, typically once daily before meals, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with underlying cardiac conditions, hepatic impairment, or known hypersensitivity to either component. Regular monitoring is recommended to assess efficacy and detect potential adverse effects, including extrapyramidal symptoms or electrolyte imbalances. This combination therapy offers a comprehensive approach to managing complex gastrointestinal disorders requiring dual pharmacologic intervention.